Unresectable hepatocellular carcinoma
Conditions
Interventions
observation group:None
Sponsors
Xi'an International Medical Center Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Aged >= 18 years at the initiation of Atezo/Bev; 2.Initiating Atezo/Bev between 28 October 2020 and 31 December 2023; 3.Diagnosed with unresectable HCC as evidenced clinically or by radiology, histology or cytology before or at the initiation of Atezo/Bev. The evidence of being diagnosed as "unresectable" may include but is not limited to below: o "Unresectable" or "advanced" directly documented in the medical records o History of extrahepatic metastasis as evidenced clinically or by radiology, histology or cytology OR China Liver Cancer (CNLC) Stage IIIb; 4.At least one visit record after the initiation of Atezo/Bev;
Exclusion criteria
Exclusion criteria: 1.Diagnosed with concomitant cancer except for basal cell carcinoma before or at the initiation of Atezo/Bev; 2.Participating in interventional clinical studies before or at initiating Atezo/Bev;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Real-world overall survival;TRAE, SAE, and AE related death; | — |
Secondary
| Measure | Time frame |
|---|---|
| Demographics and vital signs;Clinical characteristics;Time to discontinuation;Time to next treatment;Serum alpha-fetoprotein (AFP) reduction;Prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) reduction;Liver function abnormality;Renal function abnormality;Hemorrhage;rwPFS;Hepatitis virus reactivation;Immune-related adverse events; | — |
Countries
China
Contacts
Public ContactHan Guohong
Xi'an International Medical Center Hospital
Outcome results
None listed